Business Model Breakdown
How Syndax Pharmaceuticals Inc Makes Money
SNDX
Market Cap
$1.7B
Annual Revenue
$172M
Profit Margin
-165.4%
Employees
270
The Short Version
Syndax Pharmaceuticals is a clinical-stage oncology company that discovers, develops, and commercializes innovative therapies for difficult-to-treat cancers. It generates revenue primarily through the direct net sales of its approved product, Revuforj, which targets specific blood cancers. Additionally, Syndax earns collaboration revenue from partners, like Menarini Group, who market its other therapies, such as Niktimvo, globally. The company heavily invests in research and development to expand its pipeline of novel cancer treatments, aiming to address unmet medical needs and capture significant market share in specialized oncology indications.
Where the Revenue Comes From
Revuforj net product revenue (~75% of Q1 2026 total revenue)
Niktimvo collaboration revenue (~25% of Q1 2026 total revenue)
Who buys: Primarily healthcare providers (oncologists, hospitals, clinics) who prescribe and administer cancer treatments to patients.
Why It Works (Competitive Advantages)
- ✔Differentiated pipeline assets with novel mechanisms of action (e.g., Revuforj, axatilimab)
- ✔Strategic collaboration with Menarini Group for Niktimvo
- ✔Strong initial commercial traction validating market acceptance
Economic Moat: Narrow (Intangible Assets/IP (patents protecting Revuforj, axatilimab, and other pipeline candidates), Switching Costs (for patients who respond well to existing therapies, though less applicable for new indications))
What Our Analysis Says
DVR Score as of May 4, 2026
Syndax shows strong commercial momentum with Revuforj and Niktimvo sales annualizing near $200 million each, validating its market opportunity in oncology with 224% YoY revenue growth. The significant narrowing of net loss in Q1 2026, beating EPS estimates, addresses prior profitability concerns and indicates a better path towards sustainable operations, despite a minor revenue miss. The company maintains a robust cash position ($352.1M), supporting its R&D and commercialization efforts. While potential dilution from a new equity plan and an increased royalty burden present minor headwinds, the improving financial trajectory and pipeline catalysts underscore its high-risk, high-reward 10x potential. The absence of specific Q1 gross margin data (a prior red flag) is noted, but the overall net loss improvement is a more critical positive, contributing to a slight score increase.